rejuvant life tabs

Age-related macular degeneration biotech raises $148m

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Clinical-stage gene therapy company announces $148  million raised in Series C financing for age-related macular degeneration.

London-based Gyroscope Therapeutics Limited, which focuses on treating diseases of the eyeannounced today it has raised $148.0 million (£107.8 million) in a Series C financing led by Forbion’s Growth Opportunities Fund [1]. It expects to consider additional capital raising options this year, which could include an initial public offering in the United States [2]. The timing and the terms of any such additional capital raising have not yet been determined and are subject to market conditions and other factors.

Longevity.Technology: Age-related macular degeneration (AMD) is a chronic disease of the eye for which a key risk factor is, obviously, age. However, the retina is part of a large, interconnected network, and research in this area can have beneficial repercussions for other research promoting genomic, proteomic, and endocrine homeostasis and leading to the treatment the adverse effects of chronic, age-related disease in humans.

Longevity-related companies researching in this area include Alkahest, Unity, Exonate and Drusolve. In addition, Life Biosciences co-founder David Sinclair showed that neurons in the eye can be reset to a youthful state with a gene therapy that induced expression of three of the Yamanaka factor proteins. Gyroscope is hoping that by triggering an increased production of complement factor I (CFI) with a single dose of GT005, production of the serine protease will be increased, countering a driver of AMD.

The financing includes Sofinnova Investments, funds and accounts advised by T Rowe Price Associates, Inc., Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona. The company also announced the appointments of Wouter Joustra, General Partner, Forbion and Maha Katabi, General Partner, Sofinnova to the Gyroscope Board of Directors.

What are Gyroscope’s plans for the funding?

Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005, the company’s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GT005 has received Fast Track designation from the FDA and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with GA. These funds will also enable Gyroscope to further advance its early stage pipeline and innovative delivery technology, including its proprietary Orbit subretinal delivery system, which is designed for precise delivery to the back of the eye. This subretinal delivery system is currently being used by Lineage Cell Therapeutics for its therapy for dry age-related macular degeneration.

“We are excited to welcome a new group of leading life sciences investors on our journey to deliver gene therapy beyond rare disease. Their investment in Gyroscope will allow us to continue building our portfolio of investigational gene therapies,” said Khurem Farooq, Chief Executive Officer, Gyroscope. “We recently announced encouraging Phase I/II clinical trial data with our lead investigational gene therapy, GT005, that give us confidence in its potential as a treatment for geographic atrophy and are continuing to advance our Phase II clinical programme [1].”

Khurem Farooq
Khurem Farooq, Chief Executive Officer, Gyroscope

Elevant

Looking to the future for age-related macular degeneration

“Just five short years ago, we created Gyroscope to develop gene therapies for some of the leading causes of blindness. Our continued investment is a reflection of the great progress this world-class team has made towards delivering on that promise,” said Chris Hollowood, Chief Investment Officer of Syncona and Chairman of Gyroscope.

“We look forward to partnering with Gyroscope’s new investors who share our excitement about the potential of the people and science to make meaningful impact in patients’ lives, and to welcoming Wouter and Maha to the Board. With the expansion of the Board it is the right time for Dominic (Schmidt) to step down from his position as Director. We thank Dominic for his key role in the launch and growth of Gyroscope and his support of the Company [1].”

“Forbion has a reputation for pioneering investment in vector-based therapies, with seed investments in AAV- and lentiviral-based companies. Gyroscope’s pipeline of investigational gene therapies is exactly the type of potentially transformative technology we look to invest in,” said Wouter Joustra, General Partner at Forbion. “With science grounded in genetics, we believe Gyroscope is well positioned to develop novel treatments for the millions of people with serious eye diseases who currently have limited or no treatment options [1].”

What can be done for age related macular degeneration?

While there is currently no cure, treatment for age-related macular degeneration can slow progression to extend vision for as long as possible. Treatment options include anti-angiogenic drugs injected into the eye, laser therapy and photodynamic laser therapy.

Elevant

[1] https://www.gyroscopetx.com/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/
[2] https://www.gyroscopetx.com/gyroscope-therapeutics-announces-additional-financing-plans/

Image credits: Bacila Vlad / Unsplash and Gyroscope

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Gerostate Alpha opens crowdfunded capital raise

Buck Institute-founded start-up Gerostate Alpha seeks to crowdfund its biotech platform. When Y Combinator so likes your ideas, it gives you $1 million to start...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

Longevity supplements report: Youth & Earth profile

Youth & Earth is keeping it natural, while slowing down aging. Over the coming weeks, we will be bringing you extracts of 11 company profiles...
Supps report ad middle